Utidelone Injection Combined With Gemcitabine in First-line Chemotherapy for Unresectable Advanced Pancreatic Cancer
Status:
Recruiting
Trial end date:
2025-09-08
Target enrollment:
Participant gender:
Summary
This trial is an efficacy and safety evaluation of the use of Utidelone injection in
combination with gemcitabine for inoperable and locally inappropriate use first-line
chemotherapy in the treatment of advanced pancreatic cancer.
Main Purpose:To evaluate the use of utidelone in combination with gemcitabine in
unresectable, advanced pancreatic cancer without progressionSurvival (PFS), overall survival
(OS), duration of response (DOR), and safety; Secondary objective: Use of utidelone in
combination with gemcitabine in patients with unresectable, advanced pancreatic cancer,
according to investigators Objective response rates (ORRs) assessed against RECIST v1.1
criteria.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine